Phyllis Ferrell is the Vice President, and Global Alzheimer’s Disease Platform Team Leader in Lilly BioMedicines. Phyllis and her team are responsible for the late-stage development and global registration of Solanezumab, Amyvid and AZD3293, including global launches and commercialization. The team is also planning for several other earlier stage assets targeted at treating patients and supporting their caregivers.
Phyllis received a Bachelor of Arts degree in economics and management from DePauw University. She received an MBA in General Management and a certificate in Public Management from the Stanford University Graduate School of Business in 2001.
In 2014, Phyllis was recognized with the Rising Star Award from the Healthcare Businesswomen’s Association. She is a member of the Indiana Chapter of the HBA, on the Board of Directors for the Indiana Chapter of the Alzheimer’s Association, a founding member of Women Against Alzheimer’s, and a wife and mother of two boys.